MT1DP and non-small cell lung carcinoma: Additionally, delivering Erastin and lncRNA MT1DP using folate-modified liposomes to enhance NSCLC cell sensitivity to ferroptosis, with MT1DP modulating the miR-365a-3p/NRF2 axis, reducing GSH, and increasing lipid ROS, which promotes ferroptosis and cancer cell death [111].